Tesamorelin (5mg/10mg)

What is Tesamorelin?

A GHRH analog studied in clinical trials of visceral and liver fat reduction.

Listed vial contents: 5mg / 10mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

What mechanisms are being studied?

Tesamorelin is a full-length GHRH(1-44) analog with a trans-3-hexenoic acid modification at the N-terminus, providing enhanced stability and resistance to enzymatic degradation. It is FDA-approved (Egrifta) for reducing excess abdominal fat in adults with HIV-associated lipodystrophy; other uses are investigational.

What are the research questions?

• HIV-associated lipodystrophy: FDA-approved as Egrifta® for reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy.
• MASLD/NASH (liver fat): The T-LIFT trial demonstrated 37% reduction in hepatic fat fraction.
• Visceral fat reduction: Specifically targets metabolically dangerous visceral adipose tissue.
• Cognitive function: The STAY trial showed significant improvements in executive function and verbal memory.

What does the published work describe?

Falutz J et al. (JAMA 2007) — 18% visceral fat reduction vs 2% increase with placebo at 26 weeks. Fourman LT et al. (Lancet Diabetes Endocrinol 2020) — T-LIFT: 37% liver fat reduction. STAY trial — Improved executive function composite scores. FDA-approved with comprehensive Phase 3 safety data.

What are the limits of this evidence?

The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.

Study references

1. Falutz J et al. JAMA 2007;298(22):2651-2662
2. Fourman LT et al. Lancet Diabetes Endocrinol 2020

These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. Generated sample reports illustrate the reporting flow and are not evidence of testing, purity or accreditation.